What is Zacks Research's Estimate for Amarin Q1 Earnings?

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Zacks Research issued their Q1 2027 EPS estimates for Amarin in a research note issued to investors on Thursday, April 24th. Zacks Research analyst R. Department forecasts that the biopharmaceutical company will post earnings per share of ($0.69) for the quarter. The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's FY2027 earnings at ($3.80) EPS.

A number of other brokerages have also issued reports on AMRN. StockNews.com started coverage on Amarin in a research report on Wednesday, April 16th. They issued a "sell" rating on the stock. The Goldman Sachs Group dropped their price target on shares of Amarin from $20.00 to $7.00 and set a "sell" rating for the company in a research note on Thursday, April 17th.

Amarin Stock Up 3.7 %

NASDAQ AMRN traded up $0.38 on Friday, reaching $10.71. The stock had a trading volume of 44,821 shares, compared to its average volume of 74,007. The firm has a market capitalization of $219.92 million, a price-to-earnings ratio of -119.00 and a beta of 1.38. Amarin has a 12-month low of $7.08 and a 12-month high of $20.60. The stock has a fifty day moving average price of $9.56 and a two-hundred day moving average price of $10.36.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($1.20). The firm had revenue of $62.31 million during the quarter, compared to analysts' expectations of $32.37 million. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%.

Hedge Funds Weigh In On Amarin

Institutional investors have recently modified their holdings of the business. Arkfeld Wealth Strategies L.L.C. grew its stake in shares of Amarin by 52.6% in the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 20,000 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Amarin during the fourth quarter worth $36,000. Generation Capital Management LLC acquired a new position in shares of Amarin during the fourth quarter worth $50,000. Stonepine Capital Management LLC acquired a new position in shares of Amarin during the fourth quarter worth $55,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Amarin during the fourth quarter worth $68,000. Institutional investors and hedge funds own 22.25% of the company's stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.